Implementation of Decade of Healthy Ageing Action Plan to Screen and Prevent Decline in Intrinsic Capacity in Elders (SPICE) Through Multisectoral Collaboration in Singapore

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age60+
SponsorNational University Hospital, Singapore

About this trial

This study evaluates the implementation of a structured community-based pathway to screen, risk stratify, and prevent decline in intrinsic capacity (IC) among adults aged 60 years and above in Singapore. Using the World Health Organization (WHO) Integrated Care for Older People (ICOPE) framework and digital screening tools, participants will undergo IC domain screening in community settings. Individuals identified with early decline will receive targeted multidomain interventions and/or referral to primary or specialist care as indicated. Participants will be followed longitudinally to assess feasibility, uptake, functional trajectories, and implementation outcomes.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

pre-frail or robust older adults who can provide consent and follow instructions

Disqualifiers

frail or with terminal illness

Trial population

Recruitment will be conducted from Active Ageing Centre and Community Centres.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • ICOPE-Based Digital Intrinsic Capacity Monitoring and Triggered Follow-up (SPICE Pathway)

    Other intervention

    Participants will undergo baseline intrinsic capacity (IC) screening using WHO ICOPE-aligned tools in community settings. Follow-up contacts/visits will occur over the study period and include: 1. Scheduled follow-up at predefined intervals (e.g., every 3, 6-12 months) for repeat IC assessment and outcome data collection; and 2. Triggered (non-scheduled) follow-up that is initiated when remote/digital monitoring indicates decline in one or more IC domains, poor adherence, or when major intercurrent clinical events are reported/identified, prompting in-depth assessment, care plan adjustment, and referral to Community Health Posts, primary care, or specialist services as appropriate.

Treatment groups

2,500 Participants
are divided into 1 treatment group
Group A: Screen and Prevent Intrinsic Capacity Decline in Elders (SPICE)1 intervention

Trial outcomes

Primary outcomes

1

Prevalence of intrinsic capacity decline at baseline (robust / pre-frail)

Proportion of participants (restricted to robust and pre-frail at baseline) with ≥1 impaired IC domain on screening; and proportion impaired by each domain (mobility, cognition, vitality, psychological, sensory).

Time frame
Baseline
2

Uptake of recommended actions (implementation effectiveness)

Proportion of participants who initiate at least one recommended action within a defined window after screening/plan (e.g., enrolment in a prescribed community programme, completion of recommended assessment, or attendance at a referred service).

Time frame
Up to 3 months post-recommendation

Secondary outcomes

1

Identification of (a set of) biomarkers of aging

Both blood biomarkers and digital markers associated with various intrinsic capacity

Time frame
30 months
2

Feasibility and reach

Proportion of individuals in each community setting complete both Step 1 and Step 2 assessment.

Time frame
30 months
3

Change in intrinsic capacity and function over time

Change in number of impaired IC domains (0-5) from baseline to follow-up.

Time frame
12 months from enrolment
4

Frailty progression

Proportion transitioning from robust → pre-frail/frail; pre-frail → frail

Time frame
over 12 months follow up

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.